Becton Dickinson & Co. (BDX) Pops 3.14% for February 12

Equities Staff |

One of the S&P 500’s big winners for Friday February 12 was Becton Dickinson & Co. (BDX) as the company’s stock climbed 3.14% to $139.58 on volume of 1.09 million shares.

The stock opened at $136.87 and saw an intraday low of $136.39 and an intraday high of $139.58. All told, the day saw a per-share gain of $4.25. The stock’s average daily volume of 1.1 million and 211.82 million shares outstanding. Becton Dickinson & Co. now has a 50-day SMA is $147.33 and 200-day SMA is $143.13, and it has a 52-week high of $157.50 and a 52-week low of $128.87.

Becton Dickinson & Co is a medical technology company, engaged in the manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, general public and clinical laboratories.

Based out of Franklin Lakes, NJ, Becton Dickinson & Co. has 49,517 employees and, after today’s trading, reached a market cap of $29.57 billion. The stock’s P/E Ratio is 41.4. Its P/S ratio is 2.56, P/B ratio is 4.09, and P/FCF ratio is -3.8.

For a complete fundamental analysis analysis of Becton Dickinson & Co., check out’s Stock Valuation Analysis report for BDX. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…